Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical Practice Guidelines in Oncology for Neuroendocrine Tumors discuss the diagnosis and management of both sporadic and hereditary NETs. This selection from the guidelines focuses on sporadic NETs of the pancreas, gastrointestinal tract, lung, and thymus.

  • 1.

    YaoJCHassanMPhanA. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol2008;26:30633072.

    • Search Google Scholar
    • Export Citation
  • 2.

    TsikitisVLWertheimBCGuerreroMA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a SEER analysis. J Cancer2012;3:292302.

    • Search Google Scholar
    • Export Citation
  • 3.

    MarxSSpiegelAMSkarulisMC. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med1998;129:484494.

  • 4.

    Donis-KellerHDouSChiD. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet1993;2:851856.

  • 5.

    AnlaufMGarbrechtNBauersfeldJ. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch2007;451(Suppl 1):S2938.

    • Search Google Scholar
    • Export Citation
  • 6.

    LarsonAMHedgireSSDeshpandeV. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet2012;82:558563.

    • Search Google Scholar
    • Export Citation
  • 7.

    JensonRTNortonJA. Carcinoid tumors and carcinoid syndrome. In: DeVitaVTHellmanSRosenbergSA eds. Cancer: Principles and Practice of Oncology Vol. 2. 6th edition. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:18131826.

    • Search Google Scholar
    • Export Citation
  • 8.

    JoyntKEMoslehiJJBaughmanKL. Paragangliomas: etiology, presentation, and management. Cardiol Rev2009;17:159164.

  • 9.

    KlimstraDSArnoldRCapellaC. Neuroendocrine neoplasms of the pancreas. In: BosmanFTCarneiroFHrubanRHTheiseND eds. WHO Classification of Tumours of the Digestive System. Lyon: IARC; 2010:322326.

    • Search Google Scholar
    • Export Citation
  • 10.

    AlexandrakiKIGrossmanAB. The ectopic ACTH syndrome. Rev Endocr Metab Disord2010;11:117126.

  • 11.

    NearyNMLopez-ChavezAAbelBS. Neuroendocrine ACTH-producing tumor of the thymus—experience with 12 patients over 25 years. J Clin Endocrinol Metab2012;97:22232230.

    • Search Google Scholar
    • Export Citation
  • 12.

    PasiekaJLMcKinnonJGKinnearS. Carcinoid syndrome symposium on treatment modalities for gastrointestinal carcinoid tumours: symposium summary. Can J Surg2001;44:2532.

    • Search Google Scholar
    • Export Citation
  • 13.

    PalaniswamyCFrishmanWHAronowWS. Carcinoid heart disease. Cardiol Rev2012;20:167176.

  • 14.

    ChotiMABobiakSStrosbergJR. Prevalence of functional tumors in neuroendocrine carcinoma: an analysis from the NCCN NET database [abstract]. J Clin Oncol2012;30(Suppl):Abstract 4126.

    • Search Google Scholar
    • Export Citation
  • 15.

    SogaJYakuwaYOsakaM. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res1999;18:133141.

  • 16.

    ThorsonAH. Studies on carcinoid disease. Acta Med Scand Suppl1958;334:1132.

  • 17.

    FlorezJCShepardJAKradinRL. Case records of the Massachusetts General Hospital. Case 17-2013. A 56-year-old woman with poorly controlled diabetes mellitus and fatigue. N Engl J Med2013;368:21262136.

    • Search Google Scholar
    • Export Citation
  • 18.

    GilliganCJLawtonGPTangLH. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol1995;90:338352.

    • Search Google Scholar
    • Export Citation
  • 19.

    SaundMSAl NatourRHSharmaAM. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Ann Surg Oncol2011;18:28262832.

    • Search Google Scholar
    • Export Citation
  • 20.

    ObergKKvolsLCaplinM. Consensus report on the use of somatostatin analogues for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol2004;15:966973.

    • Search Google Scholar
    • Export Citation
  • 21.

    MoertelCGWeilandLHNagorneyDMDockertyMB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med1987;317:16991701.

  • 22.

    SandorAModlinIM. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol1998;93:422428.

  • 23.

    MullenJTSavareseDM. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol2011;104:4144.

  • 24.

    GleesonFCLevyMJDozoisEJ. Endoscopically identified well-differentiated rectal carcinoid tumors: impact of tumor size on the natural history and outcomes. Gastrointest Endosc2014;80:144151.

    • Search Google Scholar
    • Export Citation
  • 25.

    SogaJ. Carcinoids of the rectum: an evaluation of 1271 reported cases. Surg Today1997;27:112119.

  • 26.

    YaoJCLombard-BohasCBaudinE. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol2010;28:6976.

    • Search Google Scholar
    • Export Citation
  • 27.

    Ter-MinassianMChanJAHooshmandSM. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer2013;20:187196.

    • Search Google Scholar
    • Export Citation
  • 28.

    CoskunHBostanciODilegeME. Carcinoid tumors of appendix: treatment and outcome. Ulus Travma Acil Cerrahi Derg2006;12:150154.

  • 29.

    MurraySELloydRVSippelRS. Postoperative surveillance of small appendiceal carcinoid tumors. Am J Surg2014;207:342345; discussion 345.

    • Search Google Scholar
    • Export Citation
  • 30.

    ShapiroREldarSSadotE. Appendiceal carcinoid at a large tertiary center: pathologic findings and long-term follow-up evaluation. Am J Surg2011;201:805808.

    • Search Google Scholar
    • Export Citation
  • 31.

    CwiklaJBBuscombeJRCaplinME. Diagnostic imaging of carcinoid metastases to the abdomen and pelvis. Med Sci Monit2004;10(Suppl 3):916.

    • Search Google Scholar
    • Export Citation
  • 32.

    KaltsasGRockallAPapadogiasD. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol2004;151:1527.

    • Search Google Scholar
    • Export Citation
  • 33.

    GlazerESTsengJFAl-RefaieW. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford)2011;12:427433.

    • Search Google Scholar
    • Export Citation
  • 34.

    LesurtelMNagorneyDMMazzaferroV. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford)2015;17:1722.

    • Search Google Scholar
    • Export Citation
  • 35.

    MayoSCde JongMCPulitanoC. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol2010;17:31293136.

    • Search Google Scholar
    • Export Citation
  • 36.

    SaxenaAChuaTCPereraM. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol2012;21:e131141.

    • Search Google Scholar
    • Export Citation
  • 37.

    BrentjensRSaltzL. Islet cell tumors of the pancreas: the medical oncologist’s perspective. Surg Clin North Am2001;81:527542.

  • 38.

    JansonETObergK. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol1993;32:225229.

    • Search Google Scholar
    • Export Citation
  • 39.

    KvolsLKMoertelCGO’ConnellMJ. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med1986;315:663666.

    • Search Google Scholar
    • Export Citation
  • 40.

    KhanMSEl-KhoulyFDaviesP. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther2011;34:235242.

    • Search Google Scholar
    • Export Citation
  • 41.

    O’TooleDDucreuxMBommelaerG. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer2000;88:770776.

    • Search Google Scholar
    • Export Citation
  • 42.

    RuszniewskiPIsh-ShalomSWymengaM. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology2004;80:244251.

    • Search Google Scholar
    • Export Citation
  • 43.

    WymengaANErikssonBSalmelaPI. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol1999;17:1111.

    • Search Google Scholar
    • Export Citation
  • 44.

    VinikAWolinEMAudryH. ELECT: a phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs) [abstract]. J Clin Oncol2014;32(Suppl):Abstract 268.

    • Search Google Scholar
    • Export Citation
  • 45.

    AndersonASKraussDLangR. Cardiovascular complications of malignant carcinoid disease. Am Heart J1997;134:693702.

  • 46.

    JacobsenMBNitter-HaugeSBrydePEHanssenLE. Cardiac manifestations in mid-gut carcinoid disease. Eur Heart J1995;16:263268.

  • 47.

    BhattacharyyaSToumpanakisCChilkundaD. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol2011;107:12211226.

    • Search Google Scholar
    • Export Citation
  • 48.

    RinkeAMullerHHSchade-BrittingerC. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol2009;27:46564663.

    • Search Google Scholar
    • Export Citation
  • 49.

    ArnoldRWittenbergMRinkeA. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results on long-term survival [abstract]. J Clin Oncol2013;31(Suppl):Abstract 4030.

    • Search Google Scholar
    • Export Citation
  • 50.

    CaplinMEPavelMCwiklaJB. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med2014;371:224233.

  • 51.

    JohnstonFMMavrosMNHermanJMPawlikTM. Local therapies for hepatic metastases. J Natl Compr Canc Netw2013;11:153160.

  • 52.

    JonesNBShahMHBloomstonM. Liver-directed therapies in patients with advanced neuroendocrine tumors. J Natl Compr Canc Netw2012;10:765774.

    • Search Google Scholar
    • Export Citation
  • 53.

    KennedyABesterLSalemR. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford)2015;17:2937.

    • Search Google Scholar
    • Export Citation
  • 54.

    LewisMAHubbardJ. Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol2011;2011:452343.

  • 55.

    TanerTAtwellTDZhangL. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB (Oxford)2013;15:190195.

    • Search Google Scholar
    • Export Citation
  • 56.

    LiuDMKennedyATurnerD. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. Am J Clin Oncol2009;32:200215.

    • Search Google Scholar
    • Export Citation
  • 57.

    SipersteinAERogersSJHansenPDGitomirskyA. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery1997;122:11471154; discussion 1154–1145.

    • Search Google Scholar
    • Export Citation
  • 58.

    StrosbergJRWeberJMChoiJ. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol2012;23:23352341.

    • Search Google Scholar
    • Export Citation
  • 59.

    GatesJHartnellGGStuartKEClouseME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics1999;19:399414.

    • Search Google Scholar
    • Export Citation
  • 60.

    HurSChungJWKimHC. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. J Vasc Interv Radiol2013;24:947956; quiz 957.

    • Search Google Scholar
    • Export Citation
  • 61.

    RuszniewskiPMalkaD. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion2000;62(Suppl 1):7983.

    • Search Google Scholar
    • Export Citation
  • 62.

    DevcicZRosenbergJBraatAJ. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med2014;55:14041410.

    • Search Google Scholar
    • Export Citation
  • 63.

    KalinowskiMDresslerMKonigA. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion2009;79:137142.

    • Search Google Scholar
    • Export Citation
  • 64.

    KennedyASDezarnWAMcNeillieP. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol2008;31:271279.

    • Search Google Scholar
    • Export Citation
  • 65.

    KingJQuinnRGlennDM. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer2008;113:921929.

    • Search Google Scholar
    • Export Citation
  • 66.

    MemonKLewandowskiRJMulcahyMF. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys2012;83:887894.

    • Search Google Scholar
    • Export Citation
  • 67.

    MurthyRKamatPNunezR. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol2008;19:145151.

    • Search Google Scholar
    • Export Citation
  • 68.

    RheeTKLewandowskiRJLiuDM. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg2008;247:10291035.

    • Search Google Scholar
    • Export Citation
  • 69.

    YaoJCPhanATChangDZ. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced lowto intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol2008;26:43114318.

    • Search Google Scholar
    • Export Citation
  • 70.

    PavelMEHainsworthJDBaudinE. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet2011;378:20052012.

    • Search Google Scholar
    • Export Citation
  • 71.

    ChoueiriTKJeYSonpavdeG. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol2013;24:20922097.

    • Search Google Scholar
    • Export Citation
  • 72.

    ParithivelKRamaiyaNJagannathanJP. Everolimusand temsirolimus-associated enteritis: report of three cases. J Clin Oncol2010;29:e404406.

    • Search Google Scholar
    • Export Citation
  • 73.

    SubramaniamSZellJAKunzPL. Everolimus causing severe hypertriglyceridemia and acute pancreatitis. J Natl Compr Canc Netw2013;11:59.

  • 74.

    PanzutoFRinzivilloMFazioN. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist2014;19:966974.

  • 75.

    PaulsonASBergslandEK. Systemic therapy for advanced carcinoid tumors: where do we go from here?J Natl Compr Canc Netw2012;10:785793.

    • Search Google Scholar
    • Export Citation
  • 76.

    MedleyLMorelANFarrugiaD. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer2011;104:10671070.

    • Search Google Scholar
    • Export Citation
  • 77.

    BajettaECatenaLProcopioG. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?Cancer Chemother Pharmacol2007;59:637642.

    • Search Google Scholar
    • Export Citation
  • 78.

    SunWLipsitzSCatalanoP. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol2005;23:48974904.

    • Search Google Scholar
    • Export Citation
  • 79.

    EkebladSSundinAJansonET. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res2007;13:29862991.

    • Search Google Scholar
    • Export Citation
  • 80.

    FazioNde BraudFDelle FaveGObergK. Interferon-alpha and somatostatin analogue in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?Ann Oncol2007;18:1319.

    • Search Google Scholar
    • Export Citation
  • 81.

    FjallskogMLSundinAWestlinJE. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogues. Med Oncol2002;19:3542.

    • Search Google Scholar
    • Export Citation
  • 82.

    KolbyLPerssonGFranzenSAhrenB. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg2003;90:687693.

    • Search Google Scholar
    • Export Citation
  • 83.

    FaissSPapeUFBohmigM. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol2003;21:26892696.

    • Search Google Scholar
    • Export Citation
  • 84.

    ImhofABrunnerPMarincekN. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol2011;29:24162423.

    • Search Google Scholar
    • Export Citation
  • 85.

    KrenningEPTeunissenJJMValkemaR. Molecular radiotherapy with somatostatin analogues for (neuro-)endocrine tumors. J Endocrinol Invest2005;28:146150.

    • Search Google Scholar
    • Export Citation
  • 86.

    KwekkeboomDJBakkerWHKamBL. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging2003;30:417422.

    • Search Google Scholar
    • Export Citation
  • 87.

    KwekkeboomDJTeunissenJJBakkerWH. Radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol2005;23:27542762.

    • Search Google Scholar
    • Export Citation
  • 88.

    KwekkeboomDJTeunissenJJMKamBL. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am2007;21:561573.

    • Search Google Scholar
    • Export Citation
  • 89.

    KongGThompsonMCollinsM. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). Eur J Nucl Med Mol Imaging2014;41:18311844.

    • Search Google Scholar
    • Export Citation
  • 90.

    VillardLRomerAMarincekN. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol2012;30:11001106.

    • Search Google Scholar
    • Export Citation
  • 91.

    HorschDEzziddinSHaugA. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent Results Cancer Res2013;194:457465.

    • Search Google Scholar
    • Export Citation
  • 92.

    BushnellDLJO’DorisioTMO’DorisioMS. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol2010;28:16521659.

    • Search Google Scholar
    • Export Citation
  • 93.

    GulenchynKYYaoXAsaSL. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol)2012;24:294308.

    • Search Google Scholar
    • Export Citation
  • 94.

    Bonaccorsi-RianiEApesteguiCJouret-MourinA. Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. Transpl Int2010;23:668678.

    • Search Google Scholar
    • Export Citation
  • 95.

    GedalyRDailyMFDavenportD. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg2011;146:953958.

    • Search Google Scholar
    • Export Citation
  • 96.

    LehnertT. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation1998;66:13071312.

    • Search Google Scholar
    • Export Citation
  • 97.

    Le TreutYPGregoireEBelghitiJ. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant2008;8:12051213.

    • Search Google Scholar
    • Export Citation
  • 98.

    Le TreutYPGregoireEKlempnauerJ. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg2013;257:807815.

    • Search Google Scholar
    • Export Citation
  • 99.

    RosenauJBahrMJvon WasielewskiR. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation2002;73:386394.

    • Search Google Scholar
    • Export Citation
  • 100.

    RossiREBurroughsAKCaplinME. Liver transplantation for unresectable neuroendocrine tumor liver metastases. Ann Surg Oncol2014;21:23982405.

    • Search Google Scholar
    • Export Citation
  • 101.

    YaoJCEisnerMPLearyC. Population-based study of islet cell carcinoma. Ann Surg Oncol2007;14:34923500.

  • 102.

    MooreFDScoinskiMAJosteNE. Endocrine tumors and malignancies. In: SkarinA ed. Atlas of Diagnostic Oncology. 3rd ed.Philadelphia, PA: Elsevier Science Limited; 2003.

    • Search Google Scholar
    • Export Citation
  • 103.

    HalfdanarsonTRRabeKGRubinJPetersenGM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol2008;19:17271733.

    • Search Google Scholar
    • Export Citation
  • 104.

    RehfeldJFFederspielBBardramL. A neuroendocrine tumor syndrome from cholecystokinin secretion. N Engl J Med2013;368:11651166.

  • 105.

    AlexakisNNeoptolemosJP. Pancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol2008;22:183205.

  • 106.

    KulkeMHBendellJKvolsL. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol2011;4:29.

  • 107.

    BerniniGPMorettiAFerdeghiniM. A new human chromogranin ‘A’ immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer2001;84:636642.

    • Search Google Scholar
    • Export Citation
  • 108.

    CampanaDNoriFPiscitelliL. Chromogranin A: is it a useful marker of neuroendocrine tumors?J Clin Oncol2007;25:19671973.

  • 109.

    NeharDLombard-BohasCOlivieriS. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf)2004;60:644652.

    • Search Google Scholar
    • Export Citation
  • 110.

    YaoJCPavelMPhanAT. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab2011;96:37413749.

    • Search Google Scholar
    • Export Citation
  • 111.

    JensenRTFrakerDL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA1994;271:14291435.

    • Search Google Scholar
    • Export Citation
  • 112.

    OsefoNItoTJensenRT. Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep2009;11:433441.

  • 113.

    SimmonsLHGuimaraesARZukerbergLR. Case records of the Massachusetts General Hospital. Case 6-2013. A 54-year-old man with recurrent diarrhea. N Engl J Med2013;368:757765.

    • Search Google Scholar
    • Export Citation
  • 114.

    RoschTLightdaleCJBotetJF. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med1992;326:17211726.

  • 115.

    DoppmanJLChangRFrakerDL. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med1995;123:269273.

    • Search Google Scholar
    • Export Citation
  • 116.

    CryerPEAxelrodLGrossmanAB. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab2009;94:709728.

    • Search Google Scholar
    • Export Citation
  • 117.

    StehouwerCDLemsWFFischerHR. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh)1989;121:3440.

    • Search Google Scholar
    • Export Citation
  • 118.

    PallaisJCBlakeMADeshpandeV. Case records of the Massachusetts General Hospital. Case 33-2012. A 34-year-old woman with episodic paresthesias and altered mental status after childbirth. N Engl J Med2012;367:16371646.

    • Search Google Scholar
    • Export Citation
  • 119.

    LamSLiewHKhorHT. VIPoma in a 37-year-old man. Lancet2013;382:832.

  • 120.

    KulkeMHBergslandEKYaoJC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med2009;360:195197.

  • 121.

    LeeLCGrantCSSalomaoDR. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery2012;152:965974.

    • Search Google Scholar
    • Export Citation
  • 122.

    StrosbergJRCheemaAKvolsLK. Stage I nonfunctioning neuroendocrine tumors of the pancreas: surgery or surveillance? [abstract]. J Clin Oncol2011;29(Suppl 4):Abstract 349.

    • Search Google Scholar
    • Export Citation
  • 123.

    CherenfantJStockerSJGageMK. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery2013;154:785793.

    • Search Google Scholar
    • Export Citation
  • 124.

    HaynesABDeshpandeVIngkakulT. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg2011;146:534538.

    • Search Google Scholar
    • Export Citation
  • 125.

    KuoEJSalemRR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol2013;20:28152821.

  • 126.

    FerroneCRTangLHTomlinsonJ. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?J Clin Oncol2007;25:56095615.

    • Search Google Scholar
    • Export Citation
  • 127.

    ParekhJRWangSCBergslandEK. Lymph node sampling rates and predictors of nodal metastases in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas2012;41:840844.

    • Search Google Scholar
    • Export Citation
  • 128.

    TsutsumiKOhtsukaTMoriY. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol2012;47:678685.

    • Search Google Scholar
    • Export Citation
  • 129.

    Jean-PhilippeAAlexandreJChristopheL. Laparoscopic spleen-preserving distal pancreatectomy: splenic vessel preservation compared with the Warshaw technique. JAMA Surg2013;148:246252.

    • Search Google Scholar
    • Export Citation
  • 130.

    SuAPKeNWZhangY. Is laparoscopic approach for pancreatic insulinomas safe? Results of a systematic review and meta-analysis. J Surg Res2014;186:126134.

    • Search Google Scholar
    • Export Citation
  • 131.

    EldorRGlaserBFraenkelM. Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. Clin Endocrinol (Oxf)2011;74:593598.

    • Search Google Scholar
    • Export Citation
  • 132.

    CastroPGde LeonAMTranconJG. Glucagonoma syndrome: a case report. J Med Case Rep2011;5:402.

  • 133.

    BoninsegnaLPanzutoFPartelliS. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer2012;48:16081615.

    • Search Google Scholar
    • Export Citation
  • 134.

    CasadeiRRicciCPezzilliR. Are there prognostic factors related to recurrence in pancreatic endocrine tumors?Pancreatology2010;10:3338.

    • Search Google Scholar
    • Export Citation
  • 135.

    KimSJKimJWOhDY. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung). Am J Clin Oncol2011;35:549556.

    • Search Google Scholar
    • Export Citation
  • 136.

    StrosbergJRCheemaAWeberJM. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg2012;256:321325.

    • Search Google Scholar
    • Export Citation
  • 137.

    De JongMCFarnellMBSclabasG. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg2010;252:142148.

    • Search Google Scholar
    • Export Citation
  • 138.

    YaoJCShahMHItoT. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med2011;364:514523.

  • 139.

    PommierRFWolinEMPanneerselvamA. Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): results from the RADIANT-3 trial [abstract]. J Clin Oncol2011;29(Suppl):Abstract 4103.

    • Search Google Scholar
    • Export Citation
  • 140.

    ShahMHLombard-BohasCItoT. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): impact of somatostatin analogue use on progression-free survival in the RADIANT-3 trial [abstract]. J Clin Oncol2011;29(Suppl):Abstract 4010.

    • Search Google Scholar
    • Export Citation
  • 141.

    RaymondEDahanLRaoulJL. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med2011;364:501513.

  • 142.

    RaymondENiccoliPRaoulJ. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET) [abstract]. J Clin Oncol2011;29(Suppl):Abstract 4008.

    • Search Google Scholar
    • Export Citation
  • 143.

    RichardsCJJeYSchutzFA. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol2011;29:34503456.

    • Search Google Scholar
    • Export Citation
  • 144.

    Safety information: Sutent (sunitinib malate) capsules. US Food and Drug AdministrationWeb site. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm224050.htm. Accessed November 10 2014.

    • Search Google Scholar
    • Export Citation
  • 145.

    SchutzFAJeYRichardsCJChoueiriTK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol2012;30:871877.

    • Search Google Scholar
    • Export Citation
  • 146.

    MoertelCGLefkopouloMLipsitzS. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med1992;326:519523.

    • Search Google Scholar
    • Export Citation
  • 147.

    KouvarakiMAAjaniJAHoffP. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol2004;22:47624771.

    • Search Google Scholar
    • Export Citation
  • 148.

    ChanJAStuartKEarleCC. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol2012;30:29632968.

    • Search Google Scholar
    • Export Citation
  • 149.

    KulkeMHStuartKEnzingerPC. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol2006;24:401406.

    • Search Google Scholar
    • Export Citation
  • 150.

    KulkeMHHornickJLFrauenhofferC. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res2009;15:338345.

    • Search Google Scholar
    • Export Citation
  • 151.

    StrosbergJRFineRLChoiJ. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer2011;117:268275.

    • Search Google Scholar
    • Export Citation
  • 152.

    FineRLGulatiAPKrantzBA. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol2013;71:663670.

    • Search Google Scholar
    • Export Citation
  • 153.

    SaifMWKaleyKBrennanM. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. JOP2013;14:498501.

    • Search Google Scholar
    • Export Citation
  • 154.

    ChanJABlaszkowskyLStuartK. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer2013;119:32123218.

    • Search Google Scholar
    • Export Citation
  • 155.

    BloomstonMMuscarellaPShahMH. Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg2006;10:13611370.

    • Search Google Scholar
    • Export Citation
  • 156.

    GomezDMalikHZAl-MuktharA. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford)2007;9:345351.

    • Search Google Scholar
    • Export Citation
  • 157.

    PederzoliPFalconiMBonoraA. Cytoreductive surgery in advanced endocrine tumours of the pancreas. Ital J Gastroenterol Hepatol1999;31(Suppl):S207212.

    • Search Google Scholar
    • Export Citation
  • 158.

    PerryLJStuartKStokesKRClouseME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery1994;116:11111116.

  • 159.

    MatheZTagkalosEPaulA. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation2011;91:575582.

    • Search Google Scholar
    • Export Citation
  • 160.

    PolishAVergoMTAgulnikM. Management of neuroendocrine tumors of unknown origin. J Natl Compr Canc Netw2011;9:13971402.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 559 559 73
PDF Downloads 200 200 29
EPUB Downloads 0 0 0